Stockscreener 앱 받기
1.25
9.66%
0.1101
시간 외 거래:
1.25
전일 마감가:
$1.1399
열려 있는:
$1.2
하루 거래량:
83,728
Relative Volume:
8.46
시가총액:
$4.03M
수익:
-
순이익/손실:
$-9.60M
주가수익비율:
-0.3765
EPS:
-3.32
순현금흐름:
$-8.96M
1주 성능:
+8.70%
1개월 성능:
+12.09%
6개월 성능:
-7.41%
1년 성능:
-6.02%
1일 변동 폭
$1.15
$1.28
1주일 범위
$1.10
$1.28
52주 변동 폭
$1.00
$1.75
Artelo Biosciences Inc Stock (ARTL) Company Profile
명칭
Artelo Biosciences Inc
전화
858-925-7049
주소
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-02-12 | 개시 | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's 'Preclinical Screening Platform for Pain” Program - The Manila Times
Artelo Biosciences, Inc. Announces Acceptance of ART26.12 into the National Institutes of Health?s ?Preclinical Screening Platform for Pain? Program - Marketscreener.com
Artelo Biosciences (ARTL) Stock Surges Amid Bullish Analyst Rati - GuruFocus.com
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th - The Manila Times
FABP5 inhibitor ART-26.12 exhibits activity in psoriasis models - BioWorld Online
Artelo Biosciences shares initiated with Buy by EF Hutton - Investing.com UK
EF Hutton Initiates Coverage of Artelo Biosciences (ARTL) with Buy Recommendation - MSN
Equities Analysts Offer Predictions for Stitch Fix, Inc.’s Q1 2025 Earnings (NASDAQ:SFIX) - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
Anorexia Nervosa Market Expected to Experience Major Growth - openPR
ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com Canada
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024 - MSN
ARTLW (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com
HC Wainwright Weighs in on Artelo Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:ARTL) - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Artelo Biosciences (NASDAQ:ARTL) Announces Earnings Results - Defense World
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 3,808.3% in July - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 91.5% in July - Defense World
New drug to control pain related to cancer treatment originally developed at Stony Brook gets FDA clearance - TBR News Media
UK life sciences can lead the way in global cannabinoid R&D says CRDG report - European Pharmaceutical Manufacturer
Artelo’s FABP5 inhibitor cleared to enter clinic for chemotherapy-induced peripheral neuropathy - BioWorld Online
Artelo Biosciences Inc (ARTL)’s Market Momentum: Closing Strong at 1.33, Up 2.71 - The Dwinnex
FDA greenlights Artelo Biosciences' neuropathy drug trial By Investing.com - Investing.com Nigeria
PSEG sets $0.60 quarterly dividend for Q3 2024 By Investing.com - Investing.com
Artelo Biosciences Inc (ARTL) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
FDA clears Artelo’s FABP5 inhibitor trial - Yahoo Finance
Artelo stock jumps 13% after FDA okays ART26.12 Phase 1 study (NASDAQ:ARTL) - Seeking Alpha
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor - ForexTV.com
Pharmacokinetic evaluation of novel cannabidiol formulation presented - BioWorld Online
Artelo Biosciences Presents Data From Preclinical Studies On ART12.11 At 34th Annual International Cannabinoid Research Society Symposium - Quantisnow
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium - Yahoo Finance
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform - StockTitan
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium - Quantisnow
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90 ... - The Globe and Mail
Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors - Quantisnow
Cancer Cachexia Market Report 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Pipeline, Epidemiology, and ... - openPR
Toni Thompson Nadal Sells 1444 Shares of Etsy, Inc. (NASDAQ:ETSY) Stock - Defense World
Bulldog Investors LLP Increases Position in BNY Mellon Strategic Municipal Bond Fund, Inc. (NYSE:DSM) - Defense World
Artelo Biosciences presents important new data on ART26.12TipRanks.com - TipRanks
Artelo Biosciences' (ARTL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society - GlobeNewswire Inc.
Artelo reports promising pre-clinical data on ART12.11 - Investing.com India
Artelo reports promising pre-clinical data on ART12.11 By Investing.com - Investing.com
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT ... - Yahoo Finance
Artelo Biosciences' (ARTL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Victory Capital Management Inc. Has $2.21 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update - Investing.com India
Artelo Biosciences Inc (ARTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):